{"drugs":["Blinatumomab","Blincyto"],"mono":{"0":{"id":"931306-s-0","title":"Generic Names","mono":"Blinatumomab"},"1":{"id":"931306-s-1","title":"Dosing and Indications","sub":[{"id":"931306-s-1-4","title":"Adult Dosing","mono":"<ul><li>Hospitalize patients for the first 9 days of the first cycle and the first 2 days of the second cycle; provide healthcare professional supervision or hospitalization for the start of all subsequent cycles or for reinitiation of treatment (eg, after interruption of 4 or more hours)<\/li><li><b>Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, Relapsed or refractory:<\/b> Cycle 1 (weight 45 kg or greater): 9 mcg\/day continuous IV infusion on days 1 through 7 and 28 mcg\/day continuous IV infusion on days 8 through 28; 4 weeks continuous IV infusion followed by at least 2 weeks of no treatment; premedicate with dexamethasone 20 mg IV 1 hour before the first blinatumomab dose of each cycle, before a step dose (eg, cycle 1 day 8), or when restarting an infusion after an interruption of 4 or more hours<\/li><li><b>Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, Relapsed or refractory:<\/b> Subsequent cycles (weight 45 kg or greater): 28 mcg\/day continuous IV infusion on days 1 through 28 followed by at least 2 weeks of no treatment; premedicate with dexamethasone 20 mg IV 1 hour before the first blinatumomab dose of each cycle, before a step dose (eg, cycle 1 day 8), or when restarting an infusion after an interruption of 4 or more hours; up to 2 cycles for induction followed by 3 additional cycles for consolidation (up to a total of 5 cycles)<\/li><\/ul>"},{"id":"931306-s-1-5","title":"Pediatric Dosing","mono":"Limited experience in pediatric patients "},{"id":"931306-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Cytokine release syndrome, grade 3:<\/b> Withhold treatment until resolved; restart at 9 mcg\/day for 7 days, then increase to 28 mcg\/day if toxicity has not recurred; if treatment interruption is 7 days or less, continue the same cycle to a total of 28 days, including the days before and after the interruption; if treatment interruption is longer than 7 days, start a new cycle<\/li><li><b>Cytokine release syndrome, grade 4:<\/b> Permanently discontinue treatment<\/li><li><b>Neurotoxicity, grade 3:<\/b> Withhold treatment until grade 1 or less for at least 3 days; restart at 9 mcg\/day for 7 days, then increase to 28 mcg\/day if toxicity has not recurred; if toxicity occurred at 9 mcg\/day or does not resolve in 7 days or less, permanently discontinue treatment; if treatment interruption is 7 days or less, continue the same cycle to a total of 28 days, including the days before and after the interruption; if treatment interruption is longer than 7 days, start a new cycle<\/li><li><b>Neurotoxicity, grade 4:<\/b> Permanently discontinue treatment<\/li><li><b>Seizure:<\/b> Permanently discontinue treatment if more than 1 seizure occurs<\/li><li><b>Adverse reaction, clinically relevant grade 3:<\/b> Withhold treatment until grade 1 or less; restart at 9 mcg\/day for 7 days, then increase to 28 mcg\/day if adverse reaction has not recurred; if not resolved in 14 days or less, permanently discontinue treatment; if treatment interruption is 7 days or less, continue the same cycle to a total of 28 days, including the days before and after the interruption; if treatment interruption is longer than 7 days, start a new cycle<\/li><li><b>Adverse reaction, clinically relevant grade 4:<\/b> Consider permanent discontinuation<\/li><\/ul>"},{"id":"931306-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia, Relapsed or refractory<br\/>"}]},"2":{"id":"931306-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Powder for Solution)<\/b><br\/>Cytokine release syndrome has been reported, and may be life-threatening or fatal. Severe, life-threatening, and fatal neurological toxicities have also occurred. Blinatumomab should be interrupted or discontinued as recommended.<br\/>"},"3":{"id":"931306-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931306-s-3-9","title":"Contraindications","mono":"Hypersensitivity to blinatumomab or to any component of the formulation <br\/>"},{"id":"931306-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Cytokine release syndrome, possibly life-threatening or fatal, has been reported; monitoring recommended and interruption or discontinuation may be necessary<\/li><li>-- Neurological toxicities, sometimes severe, life-threatening, or fatal, have been commonly reported; monitoring recommended and interruption or discontinuation may be necessary<\/li><li>Hematologic:<\/li><li>-- Neutropenia and febrile neutropenia, sometimes life-threatening, have been reported; monitoring recommended and interrupt therapy if prolonged neutropenia occurs<\/li><li>Hepatic:<\/li><li>-- Transient elevations in liver enzymes, including grade 3 or higher, have been reported with and without comorbid cytokine release syndrome (CRS); monitoring recommended and interruption may be necessary<\/li><li>Immunologic:<\/li><li>-- Serious infections including sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections have been commonly reported; prophylactic use of appropriate antibiotics and monitoring recommended<\/li><li>Neurologic:<\/li><li>-- Loss of consciousness may occur due to the potential for neurologic events including seizures; driving during blinatumomab therapy not recommended<\/li><li>-- Cranial MRI changes showing leukoencephalopathy have been reported, especially in patients with prior treatment with cranial irradiation and antileukemic chemotherapy<\/li><li>Other:<\/li><li>-- Infusion reactions have been reported and may be indistinguishable from manifestations of cytokine release syndrome (CRS)<\/li><li>-- Tumor lysis syndrome has occurred; pretreatment, hydration, and monitoring are recommended; interruption or discontinuation may be necessary<\/li><\/ul>"},{"id":"931306-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"931306-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931306-s-4","title":"Drug Interactions","sub":{"1":{"id":"931306-s-4-14","title":"Major","mono":"<ul><li>Alfentanil (theoretical)<\/li><li>Aminophylline (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"}}},"5":{"id":"931306-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (20%), Nausea (25%)<\/li><li><b>Hematologic:<\/b>Anemia, All grades (18%), Anemia, Grade 3 or higher (13%), Febrile neutropenia, All grades (25%), Leukopenia, All grades (9%), Leukopenia, Grade 3 or higher (8%), Neutropenia, All grades (16%), Thrombocytopenia, All grades (11%), Thrombocytopenia, Grade 3 or higher (8%)<\/li><li><b>Other:<\/b>Fever (62%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Febrile neutropenia, Grade 3 or higher (23%), Neutropenia, Grade 3 or higher (15%)<\/li><li><b>Immunologic:<\/b>Cytokine release syndrome (11%), Hypersensitivity reaction (1%)<\/li><li><b>Neurologic:<\/b>Encephalopathy (5%), Encephalopathy, Leukoencephalopathy, Headache (36%), Neurotoxicity (50% (any grade); 15% (grade 3 or higher)), Tremor (20%)<\/li><li><b>Respiratory:<\/b>Pneumonia (9%)<\/li><li><b>Other:<\/b>Infectious disease, Serious (25%), Sepsis (7%), Tumor lysis syndrome (4%)<\/li><\/ul>"},"6":{"id":"931306-s-6","title":"Drug Name Info","sub":{"0":{"id":"931306-s-6-17","title":"US Trade Names","mono":"Blincyto<br\/>"},"2":{"id":"931306-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Monoclonal Antibody Fragment<\/li><\/ul>"},"3":{"id":"931306-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931306-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931306-s-7","title":"Mechanism Of Action","mono":"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 (B-cells) and CD3 (T-cells). It connects CD3 in the T-cell receptor complex with CD19 on benign and malignant B cells to activate endogenous T cells. Blinatumomab helps form a synapse between the T cell and the tumor cell, upregulate cell adhesion molecules, produce cytolytic proteins, release inflammatory cytokines, and the proliferation of T cells, which result in redirected lysis of CD19+ cells.<br\/>"},"8":{"id":"931306-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"931306-s-8-24","title":"Distribution","mono":"Vd: 4.52 L <br\/>"},"2":{"id":"931306-s-8-25","title":"Metabolism","mono":"Metabolites: Small peptides and amino acids <br\/>"},"3":{"id":"931306-s-8-26","title":"Excretion","mono":"<ul><li>Renal excretion: negligible amounts, unchanged drug<\/li><li>Total body clearance: 2.92 L\/hr<\/li><\/ul>"},"4":{"id":"931306-s-8-27","title":"Elimination Half Life","mono":"2.11 hours <br\/>"}}},"9":{"id":"931306-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Use a 250 mL prefilled NS IV bag of polyolefin, PVC non-di-ethylhexylphthalate (non-DEHP), or ethyl vinyl acetate (EVA) only.<\/li><li>Ensure that the 250 mL prefilled NS IV bag has a starting volume of 265 to 275 mL, and add or remove NS if necessary to attain this desired volume.<\/li><li>For 9 mcg\/day preparations, aseptically transfer 5.5 mL of IV solution stabilizer to the NS IV bag. For 28 mcg\/day preparations, aseptically transfer 5.6 mL of IV solution stabilizer to the NS IV bag. Mix gently to avoid foaming. IV solution stabilizer is not for reconstitution of blinatumomab vials.<\/li><li>Reconstitute 1 vial of blinatumomab with 3 mL of preservative-free sterile water for injection (SWFI) for a final concentration of 12.5 mcg\/mL; reconstitute 2 vials for preparation of 28 mcg\/day over 48 hours. Direct SWFI toward the side of the vial, and gently swirl contents to minimize foaming; do not shake.<\/li><li>The reconstituted solution should be clear to slightly opalescent and colorless to slightly yellow. Do not use if the solution is cloudy or has precipitates.<\/li><li>The reconstituted solution may be protected from light and stored at room temperature (23 to 27 degrees C [73 to 81 degrees F]) for 4 hours or refrigerated at 2 to 8 degrees C (36 to 46 degrees F) for 24 hours.<\/li><li>For blinatumomab 9 mcg\/day infused over 24 hours at a rate of 10 mL\/hr, aseptically transfer 0.83 mL of reconstituted blinatumomab solution into the NS IV bag.<\/li><li>For blinatumomab 9 mcg\/day infused over 48 hours at a rate of 5 mL\/hr, aseptically transfer 1.7 mL of reconstituted blinatumomab solution into the NS IV bag.<\/li><li>For blinatumomab 28 mcg\/day infused over 24 hours at a rate of 10 mL\/hr, aseptically transfer 2.6 mL of reconstituted blinatumomab solution into the NS IV bag.<\/li><li>For blinatumomab 28 mcg\/day infused over 48 hours at a rate of 5 mL\/hr, aseptically transfer 5.2 mL of reconstituted blinatumomab solution into the NS IV bag (2.7 mL from 1 vial and 2.5 mL from the second vial).<\/li><li>Mix the IV bag gently to avoid foaming.<\/li><li>The prepared IV bag may be stored (including infusion time) for 48 hours at room temperature (23 to 27 degrees C [73 to 81 degrees F]) or refrigerated at 2 to 8 degrees C (36 to 46 degrees F) for 8 days.<\/li><li>Infuse through a dedicated line as a continuous IV infusion at a constant infusion rate using an infusion pump. Use pump cassettes and tubing of polyolefin, PVC non-di-ethylhexylphthalate (non-DEHP), or ethyl vinyl acetate (EVA) only. Ensure that the tubing is compatible with the infusion pump.<\/li><li>Aseptically attach the IV tubing to the IV bag with a sterile, nonpyrogenic, low protein-binding 0.2 micron in-line filter.<\/li><li>Remove air from IV bag, especially if using an ambulatory infusion pump.<\/li><li>Prime the IV line only with the infusion solution; do not prime the IV line with NS.<\/li><li>Do not flush the infusion line, especially when changing infusion bags, as it can cause excess dosage and complications.<\/li><li>Infuse at a rate of 10 mL\/hr for 24-hour infusions or 5 mL\/hr for 48-hour infusions.<\/li><\/ul>"},"10":{"id":"931306-s-10","title":"Monitoring","mono":"<ul><li>complete remission or complete remission with partial hematological recovery indicates efficacy<\/li><li>signs and symptoms of cytokine release syndrome, including associated conditions of DIC, capillary leak syndrome, and hemophagocytic lymphohistiocytosis\/macrophage activation syndrome<\/li><li>signs and symptoms of infusion reaction, which may be clinically indistinguishable from cytokine release syndrome<\/li><li>signs and symptoms of infection<\/li><li>signs and symptoms of tumor lysis syndrome<\/li><li>laboratory parameters, including WBC and absolute neutrophil count; during infusion<\/li><li>ALT, AST, gamma-glutamyl transferase, and total blood bilirubin; before and during treatment<\/li><li>signs and symptoms of neurotoxicity<\/li><\/ul>"},"11":{"id":"931306-s-11","title":"How Supplied","mono":"<b>Blincyto<\/b><br\/>Intravenous Powder for Solution: 35 MCG<br\/>"},"13":{"id":"931306-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid activities requiring mental alertness or coordination until drug effects are realized due to potential for confusion, and coordination and balance disorders.<\/li><li>Counsel patient to report symptoms of cytokine release syndrome or an infusion reaction.<\/li><li>Instruct patient to report symptoms of neurologic toxicity (ie, convulsion, speech disorders, confusion).<\/li><li>Side effects may include pyrexia, headache, peripheral edema, nausea, hypokalemia, tremor, rash, constipation, or diarrhea.<\/li><li>Tell patient to report symptoms of an infection.<\/li><li>Warn patient that infusion pump settings should not be changed as this may result in dosing errors.<\/li><\/ul>"}}}